|
COPYRIGHT 2004 The Philadelphia Inquirer
Byline: Linda Loyd
Sep. 28--Sanofi-Aventis, the world's third-largest pharmaceutical company, will keep its U.S. research and drug development headquarters in Malvern, a company official said yesterday.
The 750 scientists and researchers at the Great Valley Corporate Center in Malvern were part of Sanofi-Synthelabo SA, the French drug maker which in August bought larger rival Aventis SA for $61.9 billion.
Sanofi and Aventis agreed in April...
Read the full article for free courtesy of your local library.
| 
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
